Latest Articles
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target.
Endometriosis is a chronic, heterogeneous disease with limited non-hormonal treatment options. Drug repurposing provides an accelerated route to identify safe, tolerable, and potentially effective therapies for endometriosis. Receptor tyrosine kinase-like …
Published: Dec. 3, 2025, midnight
Emerging roles and therapeutic potential of tRNA-Derived small RNAs in reproductive system diseases: a review.
tRNA-derived small RNAs (tsRNAs) are a class of non-coding RNAs(ncRNAs) generated from precursor or mature tRNAs under stress conditions, such as starvation, hypoxia, or oxidative stress. They are broadly classified …
Published: Dec. 3, 2025, midnight
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire
Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan
Published: Dec. 2, 2025, 1:05 p.m.
Amy Schumer says she lost 50lbs to 'survive' potentially fatal disease - LADbible
Amy Schumer says she lost 50lbs to 'survive' potentially fatal disease LADbible
Published: Dec. 2, 2025, 12:46 p.m.
Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test - Femtech Insider
Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test Femtech Insider
Published: Dec. 2, 2025, 11:38 a.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer
Published: Dec. 2, 2025, 7:30 a.m.
Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia - Medical Dialogues
Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia Medical Dialogues
Published: Dec. 2, 2025, 5 a.m.
Link copied to clipboard!